pharmaphorum

JANUARY 6, 2021

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometabolic diseases. The post Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit appeared first on.

Gene Silencing 66

Gene Silencing Gene RNA Contract Manufacturing 66

pharmaphorum

FEBRUARY 18, 2022

As the industry continues to expand RNAi drug development, it is becoming more important than ever to overcome the hurdles of analytics, raw material supply, & manufacturing. Effective Strategies to Advance Analytical Development & CMC of siRNA Therapeutics. Hear expert insights from AstraZeneca & Abbvie.

Gene Silencing 52

Gene Silencing Development Drugs Clinical Development 52

pharmaphorum

SEPTEMBER 1, 2021

As well as the access agreement for high-risk patients, the Novartis deal also covers a large-scale trial of the PCSK9 inhibitor and the creation of a consortium with academic groups aimed at improving the manufacturing of oligonucleotide drugs in the UK.

Drugs 98

Drugs Trials Gene Silencing Genetics 98

Roots Analysis

OCTOBER 22, 2023

RNA interference (RNAi) Therapeutics : Fundamentally, RNAi is a natural process of post-transcriptional gene silencing, involving short strands of nucleic acids. Cells use this process to silence and / or inhibit gene expression, via targeted degradation of specific (unwanted) mRNA molecules.

RNA 40

RNA Protein Genetics Gene Expression 40

The Pharma Data

NOVEMBER 24, 2020

About RNAi RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Until today, there were no approved pharmaceutical therapies for PH1.

FDA Approval 52

FDA Approval Production RNA Medicine 52